United Therapeutics Corporation UTHR
475.45
3.24
0.69%
as of 25 Sep
- Market cap
- $20.3B
- P/E
- 15.7×
Follow UTHR
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
17.89 | 20.22 | 16.14 | 14.70 |
+8 more quarters Free account |
P/S ratio |
7.32 | 8.14 | 6.78 | 5.87 | |
P/FCF ratio |
21.22 | 25.50 | 20.85 | 16.52 | |
P/Operating CF |
73.60 | 55.68 | 62.35 | 32.67 | |
P/B ratio |
3.61 | 4.37 | 3.04 | 2.79 | |
Price to Tangible BV |
3.67 | 4.46 | 3.09 | 2.84 | |
EV/Sales |
6.57 | 7.55 | 5.96 | 5.08 | |
EV/EBITDA |
13.88 | 15.71 | 12.02 | 10.08 | |
EV/Operating CF |
12.30 | 15.31 | 12.15 | 10.21 | |
EV/FCF |
19.05 | 23.67 | 18.32 | 14.30 | |
Quick Ratio |
4.89 | 4.12 | 5.83 | 5.61 | |
Current Ratio |
5.73 | 4.79 | 6.60 | 6.40 | |
Net Debt/EBITDA |
(7.50) | (6.18) | (7.70) | (6.74) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.42 | 0.44 | 0.42 | 0.43 | |
Operating CF/Net income |
0.94 | 1.69 | 0.95 | 1.66 | |
Capex/Depreciation |
(4.46) | (4.46) | (7.58) | (9.86) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
18.68% | 17.68% | 17.65% | 15.95% | |
Selling, General and Administrative Expense of Revenue |
26.39% | 23.56% | 24.12% | 22.84% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.01 | 0.02 | |
Share Based Compensation of Revenue |
5.54% | 4.34% | 4.94% | 4.89% | |
Graham Net Nets |
0.12 | 0.08 | 0.14 | 0.15 | |
Graham Number |
319.94 | 299.15 | 329.81 | 310.67 | |
Earnings Yield |
5.59% | 4.94% | 6.19% | 6.80% | |
Free Cash Flow Yield |
4.71% | 3.92% | 4.80% | 6.05% | |
Revenue per Share |
18.39 | 17.97 | 17.84 | 18.25 | |
Operating CF per Share |
7.36 | 10.65 | 7.81 | 12.83 | |
Capex per Share |
(2.54) | (2.32) | (3.90) | (4.93) | |
Free Cash Flow per Share |
4.83 | 8.33 | 3.91 | 7.90 | |
Cash per Share |
62.50 | 49.51 | 65.92 | 63.19 | |
Shareholders Equity per Share |
150.24 | 135.66 | 160.19 | 150.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
150.24 | 135.66 | 160.19 | 150.46 | |
Free Cash Flow |
205.60 | 362.50 | 173.30 | 346.10 | |
Working Capital |
2,875.90 | 2,272.90 | 3,141.90 | 2,947.70 | |
Capital Expenditures |
(108.00) | (100.80) | (172.90) | (216.00) | |
Net Current Asset Value |
2,663.90 | 2,058.90 | 2,918.70 | 2,733.10 | |
EV/EBIT |
14.78 | 16.68 | 12.71 | 10.64 | |
Capex to Sales |
0.14 | 0.13 | 0.22 | 0.27 | |
Net Profit Margin |
42.51% | 35.18% | 46.10% | 42.36% | |
Price to Operating Income |
16.47 | 17.97 | 14.46 | 12.29 | |
| Other line items | |||||
Average Receivables |
344.80 | 317.00 | 314.75 | 319.75 | |
Average Payables |
464.90 | 432.65 | 416.25 | 415.95 | |
Average Inventory |
181.50 | 171.85 | 170.50 | 161.60 | |
Average Assets |
7,564.05 | 7,229.05 | 7,622.00 | 7,237.10 | |
Average Common Equity |
6,786.95 | 6,354.15 | 6,770.10 | 6,345.55 |
Columns are period end dates